RESUMEN
OBJECTIVES: Depression is highly prevalent in non-Hodgkin's lymphoma (NHL) patients undergoing chemotherapy. The social stress associated with malignancy induces neurovascular pathology promoting clinical levels of depressive symptomatology. The purpose of this study was to establish an effective depressive symptomatology risk prediction model to those patients. METHODS: This study included 238 NHL patients receiving chemotherapy, 80 of whom developed depressive symptomatology. Different types of variables (sociodemographic, medical, and psychosocial) were entered in the models. Three prediction models (support vector machine-recursive feature elimination model, random forest model, and nomogram prediction model based on logistic regression analysis) were compared in order to select the one with the best predictive power. The selected model was then evaluated using calibration plots, ROC curves, and C-index. The clinical utility of the nomogram was assessed by the decision curve analysis (DCA). RESULTS: The nomogram prediction has the most efficient predictive ability when 10 predictors are included (AUC = 0.938). A nomogram prediction model was constructed based on the logistic regression analysis with the best predictive accuracy. Sex, age, medical insurance, marital status, education level, per capita monthly household income, pathological stage, SSRS, PSQI, and QLQ-C30 were included in the nomogram. The C-index was 0.944, the AUC value was 0.972, and the calibration curve also showed the good predictive ability of the nomogram. The DCA curve suggested that the nomogram had a strong clinical utility. CONCLUSIONS: We constructed a depressive symptomatology risk prediction model for NHL chemotherapy patients with good predictive power and clinical utility.
Asunto(s)
Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Depresión/etiología , Linfoma no Hodgkin/tratamiento farmacológico , Linfoma no Hodgkin/psicología , Cuerpo Médico , Modelos Psicológicos , Psicoterapia , Femenino , Humanos , Masculino , Tamizaje Masivo , Persona de Mediana Edad , Reproducibilidad de los ResultadosRESUMEN
Thyroid hormone disrupting compounds in water sources is a concern. Thyroid hormone (TH) agonist and antagonist activities of water sources from the Yangtze River, Huaihe River, Taihu Lake and ground water in the Yangtze River Delta region were evaluated by use of a TH reporter gene assay based on the green monkey kidney fibroblast (CV-1). While weak TH receptor (TR) agonist potency was observed in only one of 15 water sources, antagonist potency was present in most of the water sources. TR antagonist equivalents could be explained by the presence of dibutyl phthalate (DBP), with concentrations ranging from 2.8×10(1) to 1.6×10(3) µg DBP /L (ATR-EQ(50)s). None of the ground waters exhibited TH agonist potencies while all of the samples from Taihu Lake displayed notable TR antagonist potencies. To identify the responsible thyroid active compounds, instrumental analysis was conducted to measure a list of potential thyroid-disrupting chemicals, including organochlorine (OC) pesticides and phthalate esters. Combining the results of the instrumental analysis with those of the bioassay, DBP was determined to account for 17% to 144% of ATR-EQ(50)s in water sources. Furthermore, ATR-EQ(20-80) ranges for TR antagonist activities indicated that samples from locations WX-1 and WX-2 posed the greatest health concern and the associated uncertainty may warrant further investigation.
Asunto(s)
Disruptores Endocrinos/análisis , Ácidos Ftálicos/análisis , Ríos/química , Contaminantes Químicos del Agua/análisis , Animales , Bioensayo , Línea Celular , Disruptores Endocrinos/química , Disruptores Endocrinos/toxicidad , Monitoreo del Ambiente , Agua Subterránea/química , Humanos , Lagos/química , Plaguicidas , Ácidos Ftálicos/toxicidad , Receptores de Hormona Tiroidea/antagonistas & inhibidores , Medición de Riesgo , Hormonas Tiroideas/metabolismo , Contaminantes Químicos del Agua/toxicidad , Abastecimiento de Agua/análisis , Abastecimiento de Agua/estadística & datos numéricosRESUMEN
<p><b>OBJECTIVE</b>Ganciclovir is a first line drug for treatment of cytomegalovirus (CMV) infection. This study aimed to compare the efficacy and side effects of relatively low and high doses of Ganciclovir in the treatment of neonatal congenital CMV infection.</p><p><b>METHODS</b>37 neonates with congenital CMV infection were randomly assigned to high-dose (n = 19) and low-dose Ganciclovir groups (n = 18). The high-dose Ganciclovir group was injected with Ganciclovir of 7.5 mg/kg in the inducement phase and of 10 mg/kg in the maintaining phase. The low-dose Ganciclovir group was injected with Ganciclovir of 5 mg/kg in the inducement and the maintaining phases. The efficacy and side effects were observed in the two groups.</p><p><b>RESULTS</b>The results of different doses of GCV treatment of congenital CMV infection in symptomatic by the clinical symptoms were improved, high-dose treatment group CMV-IgM negative rate of 89.5%, CMV-DNA negative rate of 73.7%; low-dose treatment group CMV-IgM switch negative rate of 83.3%, CMV-DNA negative rate was 77.8%, no significant difference between the two groups. Low-dose GCV treatment of congenital CMV infection in newborns with symptomatic side effects than high dose GCV, the low dose group neutropenia, anemia, thrombocytopenia was lower than the high dose group, the difference was significant (P < 0.05).</p><p><b>CONCLUSION</b>Low- dose GCV treatment of symptomatic congenital CMV infection with high-doses of the same clinical efficacy, and less side effects than high-doses of GCV.</p>
Asunto(s)
Femenino , Humanos , Recién Nacido , Masculino , Antivirales , Infecciones por Citomegalovirus , Quimioterapia , Virología , ADN Viral , Sangre , GanciclovirRESUMEN
Surveys were carried out in 2003-2006 to better understand the epidemiology of hantaviruses in the Inner Mongolia Autonomous Region of China (Inner Mongolia). Hemorrhagic fever with renal syndrome (HFRS) was first reported in this region in 1955 and has been an important public health problem here since then. During 1955-2006, 8,309 persons with HFRS were reported in Inner Mongolia (average incidence rate 0.89/100,000), and 261 (3.14%) died. Before the 1990s, all HFRS cases occurred in northeastern Inner Mongolia. Subsequently, HFRS cases were registered in central (1995) and western (1999) Inner Mongolia. In this study, hantaviral antigens were identified in striped field mice (Apodemus agrarius) from northeastern Inner Mongolia and in Norway rats (Rattus norvegicus) from middle and western Inner Mongolia. Phylogenetic analysis of hantaviral genome sequences suggests that HFRS has been caused mainly by Hantaan virus in northeastern Inner Mongolia and by Seoul virus in central and western Inner Mongolia.
Asunto(s)
Virus Hantaan , Fiebre Hemorrágica con Síndrome Renal/epidemiología , Enfermedades de los Roedores , Virus Seoul , Animales , Antígenos Virales/análisis , China/epidemiología , Virus Hantaan/clasificación , Virus Hantaan/genética , Virus Hantaan/inmunología , Virus Hantaan/aislamiento & purificación , Fiebre Hemorrágica con Síndrome Renal/transmisión , Fiebre Hemorrágica con Síndrome Renal/virología , Humanos , Incidencia , Pulmón/virología , Murinae/virología , Filogenia , Ratas/virología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Enfermedades de los Roedores/epidemiología , Enfermedades de los Roedores/transmisión , Enfermedades de los Roedores/virología , Virus Seoul/clasificación , Virus Seoul/genética , Virus Seoul/inmunología , Virus Seoul/aislamiento & purificación , Análisis de Secuencia de ADNRESUMEN
OBJECTIVE: In order to better understand the epidemiological features of Hantviruses in Inner Mongolia. METHODS: Epidemiological surveillance data during the period of the past 52 years were analyzed. An epidemiological survey was carried out in the main epidemic areas in 2005. RESULTS: A total of 8310 hemorrhagic fever with renal syndrome (HFRS) cases were reported in Inner Mongolia from 1955 to 2006, and distributed in 61 counties. HFRS cases were mainly distributed in the east part of Inner Mongolia before 1990. However, HFRS cases had occurred in the middle and western parts since 1990. Hulunbeier prefecture, from the eastern part of Inner Mongolia, had been the most severe area being hit by HERS since the first outbreak in 1955, with 7369 cases reported over the past 52 years, and accounted for 88.68% of the total cases in the whole autonomous region. Although no HFRS cases had been reported before 1999 in Bayannaoer which located in the western part of Inner Mongolia, a total of 95 cases were reported in 2005. Hantavirus antigens had been detected in 11 species of rodents so far,including Apodemus agrarius, Rattus norvegicus, Mus Musculus, Cricetulus barabensis, meriones meridianus, Microtus maximowiczii , Clethrionomys rutilus, Apodemus peninsulae, Phodopus roborvskii, Dipus sagitta and Allactaga sibirica. CONCLUSION: Results suggested that the epidemics might remain at a relatively high level in the years to come in Inner Mongolia. Furthermore, there might be other types of Hantaviruses in addition to the already identified Seoul viral type in this area.
Asunto(s)
Fiebre Hemorrágica con Síndrome Renal/epidemiología , Zoonosis/epidemiología , Animales , China/epidemiología , Brotes de Enfermedades , Orthohantavirus/aislamiento & purificación , Humanos , Epidemiología Molecular , Enfermedades de los Roedores/epidemiología , Enfermedades de los Roedores/virología , Roedores/virología , Zoonosis/virologíaRESUMEN
Antiangiogenesis is a promising strategy of cancer treatment. Vascular endothelial growth factor receptor [fetal liver kinase/kinase-inserting domain-containing receptor (KDR)] is a tyrosine kinase receptor and has been strongly implicated in tumor angiogenesis. In this study, we report that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (ON-III), extracted from the dried flower Cleistocalyx operculatus, used in traditional Chinese medicine, reversibly inhibited KDR tyrosine kinase phosphorylation, but epidermal growth factor receptor tyrosine kinase phosphorylation was unaffected under the same concentrations of ON-III. ON-III also inhibited mitogen-activated protein kinase (MAPK) and AKT activation of KDR signal transduction in downstream molecules without reduced total MAPK and AKT. The results in vitro showed that ON-III inhibited growth of human vascular endothelial HDMEC cells in the presence of VEGF preferentially, compared with epidermal growth factor. Systemic administration of ON-III at nontoxic doses in nude mice resulted in inhibition of subcutaneous tumor growth of human hepatocarcinoma Bel7402 and lung cancer GLC-82 xenografts. The tumor vessel density decreased, as determined by immunohistochemical staining, for CD31 after ON-III treatment. These results indicated that ON-III inhibited KDR tyrosine kinase, shut down KDR-mediated signal transduction, and inhibited tumor growth of human xenografts in vivo.